James Wassil | Chief Operating Officer
SutroVax, Inc

Jim Wassil, MS, MBA is Chief Operating Officer at Sutrovax, Inc.  In this role, Mr. Wassil will lead leading clinical development, medical affairs, regulatory affairs, quality assurance and program management activities for several preclinical candidates including Pneumococcal Conjugate and Group A Streptococcus Vaccines.

Mr. Wassil brings extensive experience in the development and commercialization of vaccines having spent the past three decades in positions of increasing responsibility in the vaccine divisions of Merck, Novartis, and Pfizer. He was responsible for the development and launch of Menveo, the meningococcal conjugate vaccine, Bexsero along with the ABCWY vaccine candidate while at Novartis Vaccines. Most recently he was responsible for market access, policy, pricing, tender negotiations, epidemiology and health outcomes, as the business unit lead for Pfizer Vaccines, where he was responsible for the full vaccine portfolio, including the pneumococcal conjugate vaccine franchise (Prevnar 13). Previously he led international marketing for the pediatric vaccine franchise at Merck Vaccines where he launched RotaTeq, a vaccine for rotavirus gastroenteritis in infants and children, and held other technical and operational roles of increasing responsibility.

Mr. Wassil earned a bachelor of science degree in chemistry/biology with high honors from the University of Notre Dame and a master of science degree in bio-organic chemistry and a master of business administration degree, both from Lehigh University.  In 2014, James received the VIVA Award as Novartis’ top scientist in 2014 for development and approval of Bexsero®.  He also was an ACE Finalist (Secretary of State Award for Corporate Excellence) for his role in conducting an effectiveness study of RotaTeq® in Nicaragua.